Metoprolol Succinate Extended-Release Tablets Recalled for Failed Dissolution
Ascend Laboratories is recalling Metoprolol Succinate Extended-Release Tablets 25 mg nationwide because the tablets failed to meet dissolution specifications, which may affect how the medication releases in the body.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The hazard is a manufacturing defect (failed dissolution) affecting drug efficacy rather than safety; the source text states only that the product failed specifications without reporting adverse events or hospitalization.
Plain-English summary
Ascend Laboratories, LLC is recalling Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, distributed nationwide in the United States. The recall affects 9,216 bottles with Lot #21143093 and expiration date of March 2023. The product was manufactured by Alkem Laboratories Ltd. in Mumbai, India.
The tablets failed to meet dissolution specifications. Dissolution is the rate at which the tablet breaks down and releases the active ingredient in the body. When a tablet does not dissolve as intended, it may not deliver the medication properly.
Consumers who have this product should consult their healthcare provider or pharmacist. Do not stop taking the medication without medical guidance, as abruptly stopping metoprolol succinate can be harmful. Your healthcare provider can advise whether your specific supply is affected and recommend next steps.
The recalled product
- Product
- METOPROLOL SUCCINATE (METOPROLOL SUCCINATE ER TABLETS)
- Brand
- METOPROLOL SUCCINATE
- Manufacturer
- Ascend Laboratories, LLC
- Affected units
- 9,216
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 21143093
- Exp. March 2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · METOPROLOL SUCCINATE
- ModerateMetoprolol Succinate Extended-Release Tablets Recalled Due to Failed Dissolution
FDA (Drugs) · 2026-05-20
- HighTeva metoprolol succinate 50 mg tablets failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighTeva metoprolol succinate 25 mg tablets failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighTeva metoprolol succinate 100 mg tablets failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighTeva metoprolol succinate 200 mg tablets failed dissolution specifications
FDA (Drugs) · 2026-03-11
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · failed dissolution
See all →- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- SevereGolden State Medical Supply Recalls Prasugrel Tablets for Failed Dissolution
FDA (Drugs) · 2026-09-09
- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10